Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026

(NASDAQ:ALT) Altimmune, Inc. announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted as an oral presentation at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2026, taking place November 5-9, 2026. The RECLAIM trial is a randomized, double-blind, placebo-controlled study evaluating once-weekly pemvidutide 2.4 mg versus placebo over 24 weeks in approximately 100 patients with BMI >25 kg/m2. In topline results announced in July 2026, pemvidutide achieved the trial’s primary endpoint of a statistically significant reduction in heavy drinking days (HDD) per week compared with placebo. Pemvidutide also met key secondary endpoints validated by the U.S. Food and Drug Administration (FDA) as registrational endpoints, including reduction in World Health Organization (WHO) Risk Drinking Levels and zero HDD, with a generally favorable tolerability profile. The late-breaking oral presentation, titled 'Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial,' will be delivered by Henry R. Kranzler, M.D., Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine, on Monday, November 9, 2026, at 10:30 a.m. MT / 12:30 p.m. ET. A copy of the presentation will be accessible on the Events section of the Altimmune website immediately following the session. Altimmune is scheduled to meet with the FDA in December for an End-of-Phase 2 meeting to discuss the Phase 3 registrational program for pemvidutide in AUD. RECLAIM (NCT06987513) is the first Phase 2 multicenter study evaluating a dual glucagon-GLP-1 agonist in AUD to report results. The primary endpoint was the change from baseline in the average number of heavy drinking days per week, with secondary endpoints including the proportion of patients achieving a 2-level reduction in WHO Risk Drinking Levels, zero HDD, and absolute change from baseline in average levels of phosphatidylethanol (PEth), an objective serum biomarker of alcohol intake. The FDA recognizes the 2-level reduction in WHO risk drinking levels and zero HDD as registrational endpoints. Pemvidutide is a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), AUD, and alcohol-associated liver disease (ALD). The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, Altimmune announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial of pemvidutide in MASH was initiated. In August 2026, Altimmune announced completion of enrollment of the RESTORE Phase 2 trial in ALD.

Appointment of Non-Executive Director

(AIM: ALT) Altitude Group plc announced the appointment of Max Roberts as an Independent Non-Executive Director with effect from 30th June 2026. Max Roberts recently served as Chief Operating Officer of IFS and joined IFS in January 2024 from Stripe, where he was Chief Executive of the UK business and subsequently led the EMEA region. He has also served as a Non-Executive Director of UK Finance. Alexander Brennan is the Non-Executive Chairman of Altitude, and Robert Wigley is an independent Non-Executive Director. As at the date of this announcement, Mr Roberts does not hold any interest in the share capital of the Company. The company states that Max's appointment strengthens the Board in areas relevant to the Group's next phase of growth. The company projects that Max's experience in payments, enterprise software, and creating value from data at scale will support the Group as it executes its technology-led strategy.

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune, Inc. announced the pricing of its underwritten public offering, which includes 64,250,000 shares of common stock and accompanying warrants, as well as up to 10,750,000 pre-funded warrants and accompanying warrants. The exercise price for each pre-funded warrant is $0.001, and the accompanying common stock warrants have an exercise price of $3.00 per share. The combined offering price is $3.00 per share and warrant, or $2.999 per pre-funded warrant and warrant. The offering is expected to close on or about April 24, 2026, subject to customary closing conditions.

Altimmune Announces Proposed Underwritten Public Offering of Securities

Altimmune, Inc. announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants. The offering also includes pre-funded warrants in lieu of common stock to certain investors. All securities in the proposed offering are being offered by Altimmune. The completion and terms of the offering are subject to market and other conditions, and there is no assurance the offering will be completed.